DSM-Firmenich stock gains after stronger 2026 sales outlook
Published on 11/05/2026 at 17:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth outlook strengthens after Q3
- Third-quarter like-for-like sales growth reached 5 percent on volume-led momentum.
- Adjusted EBITDA rose 8 percent like-for-like, while the margin target remains around 20 percent.
- Share cancellations planned for the first quarter of 2027 could reduce issued shares by approximately 2.6 percent.
dsm-firmenich raised its 2026 sales outlook on Wednesday, November 4, after volume-led growth in the third quarter. The company said momentum continued across its portfolio, while its full-year margin and cash targets stayed intact, according to its Q3 trading update.
What changed after the Q3 update
Continuing operations delivered like-for-like sales growth of 5 percent in the third quarter, matching the year-to-date pace. Growth was volume-led and supported by high win rates on customer briefs and strong performance from regional and local accounts.
Third-quarter sales reached 2,368 million euros, compared with 2,238 million euros a year earlier. Adjusted EBITDA increased 8 percent on a like-for-like basis to 482 million euros from 458 million euros. The adjusted EBITDA margin was 20.4 percent, although foreign-exchange movements created an 80-basis-point headwind versus the prior-year quarter.
Targets hold into the final quarter
Management lifted its full-year 2026 like-for-like sales-growth outlook to around 5 percent from the previous range of 2 percent to 4 percent. The company maintained its adjusted EBITDA margin target at around 20 percent and its adjusted gross operating free cash flow-to-sales target at 11 percent to 12 percent.
For investors, the updated outlook improves the near-term growth profile, but currency movements, regional demand and execution of the cost program remain central to the margin path. The share repurchase program was completed on September 30, and shares bought for capital reduction are expected to be cancelled by the end of the first quarter of 2027.
Market indication and next milestone
The real-time quote of DSM-Firmenich stock showed the stock at 112.98 euros on Lang & Schwarz at 17:04 CET on Thursday, November 5.
The next scheduled company milestone is publication of the full-year 2026 results on February 18, 2027.
The Swiss market remains an important reference point for investors tracking the company across its international listings; see current SMI market coverage.
Find more news and analyses on DSM-Firmenich stock.
DSM-Firmenich key figures
- Company: dsm-firmenich AG
- ISIN: CH1216478797
- Exchange listings: Euronext Amsterdam and SIX Swiss Exchange
- Lang & Schwarz quote: 112.98 euros at 17:04 CET on Thursday, November 5, 2026
- Q3 like-for-like sales growth: 5 percent
- Q3 adjusted EBITDA: 482 million euros
- FY 2026 sales-growth outlook: Around 5 percent
- FY 2026 adjusted EBITDA margin target: Around 20 percent
